Dr. Brian Layden one of three researchers awarded funding by Chicago Biomedical Consortium

///Dr. Brian Layden one of three researchers awarded funding by Chicago Biomedical Consortium

Dr. Brian Layden one of three researchers awarded funding by Chicago Biomedical Consortium

Dr. Brian Laydan is one of three researchers from the University of Illinois College of Medicine that will receive funding from the Chicago Biomedical Consortium through the group’s Accelerator Awards competition.

Dr. Brian Layden

The Chicago Biomedical Consortium is made up of researchers at UIC, Northwestern University and the University of Chicago who work together to make discoveries that will transform biomedical research and improve health.

The consortium launched a new Accelerator Award program in 2018 to support translational research and provide university researchers with early commercial guidance. The awards will provide up to $100,000 for one year and will be used to support the initial — and therefore highest risk — stage of commercially directed research focused on the development of a therapeutic or an associated biomarker or diagnostic.

The program received 32 letters of intent, and nine researchers who submitted letters were asked to present to the Chicago Biomedical Consortium Accelerator Network in early February. Four researchers from the University of Illinois at Chicago presented, and were asked to submit full proposals. Ultimately, three were selected to receive funding. The Consortium selected five projects overall to fund.

Dr. Layden’s group is developing a new treatment for Type 2 diabetes based on their discovery that New approaches to treat Type 2 diabetes (T2D) are needed. Our group has shown that a protein called FFA3 mediates insulin secretion and plays a role in the development of insulin resistance — a major characteristic of Type 2 diabetes. Layden’s group has shown that blocking this protein could have beneficial effects. They will screen for small drug molecules that can block FFA3. Future work will develop these molecules into compounds that are suitable for testing in vivo and eventually in pre-clinical and clinical studies.

View full article here.

More News
By |2018-07-18T11:36:57+00:00June 6th, 2018|Department of Medicine, DOM Endocrinology, Diabetes and Metabolism News|Comments Off on Dr. Brian Layden one of three researchers awarded funding by Chicago Biomedical Consortium